AR048638A1 - Anticuerpos anti-glicoproteina vi y metodos de los mismos - Google Patents
Anticuerpos anti-glicoproteina vi y metodos de los mismosInfo
- Publication number
- AR048638A1 AR048638A1 ARP050101720A ARP050101720A AR048638A1 AR 048638 A1 AR048638 A1 AR 048638A1 AR P050101720 A ARP050101720 A AR P050101720A AR P050101720 A ARP050101720 A AR P050101720A AR 048638 A1 AR048638 A1 AR 048638A1
- Authority
- AR
- Argentina
- Prior art keywords
- gpvi
- monoclonal antibody
- antibodies
- peptide
- variant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anticuerpos generados contra la glicoproteína VI (GPVI) de la membrana plaquetaria, métodos para producir los anticuerpos anti-GPVI, y el uso de estos anticuerpos como agentes de investigacion e inmunoterapéutica, en particular, como agentes terapéuticos antitromboticos. Reivindicacion 1: Un anticuerpo monoclonal específico para un polipéptido o péptido de GPVI, o una variante de los mismos que existe en la naturaleza, donde el anticuerpo monoclonal inhibe la agregacion plaquetaria inducida por colágeno a una IC50 de menos de 7 microg/ml, y donde el anticuerpo monoclonal se une específicamente al polipéptido, o péptido de GPVI o a una variante de los mismos que existe en la naturaleza, con una Kd de menos de 10-8 M. Reivindicacion 14: Un método para producir un anticuerpo monoclonal específico para un polipéptido o péptido de GPVI, o una variante de los mismos que existe en la naturaleza que comprende: inmunizar un huésped deficiente en GPVI con un antígeno de GPVI y obtener el anticuerpo monoclonal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56617104P | 2004-04-29 | 2004-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048638A1 true AR048638A1 (es) | 2006-05-10 |
Family
ID=35149339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101720A AR048638A1 (es) | 2004-04-29 | 2005-04-29 | Anticuerpos anti-glicoproteina vi y metodos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7611707B2 (es) |
| EP (1) | EP1745076B1 (es) |
| JP (1) | JP2008507476A (es) |
| KR (1) | KR101194446B1 (es) |
| CN (1) | CN1964990B (es) |
| AR (1) | AR048638A1 (es) |
| AU (1) | AU2005243193B2 (es) |
| CA (1) | CA2565063A1 (es) |
| ES (1) | ES2389047T3 (es) |
| RU (1) | RU2407752C2 (es) |
| TW (1) | TW200606177A (es) |
| WO (1) | WO2005111083A2 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| CA2635599C (en) * | 2006-01-13 | 2014-06-17 | Irm Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
| WO2007116779A1 (ja) * | 2006-03-31 | 2007-10-18 | Mochida Pharmaceutical Co., Ltd. | 新規血小板活性化マーカー及びその測定方法 |
| EP1916259A1 (en) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| JP2008249552A (ja) * | 2007-03-30 | 2008-10-16 | Otsuka Pharmaceut Co Ltd | 可溶性血小板膜糖タンパク質ｖｉの測定系 |
| KR20100075585A (ko) * | 2007-10-31 | 2010-07-02 | 오쓰까 세이야꾸 가부시키가이샤 | 당단백질 ｖｉ (ｇｐｖｉ) 억제제의 용도 |
| GB2460915B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| EP2397495A1 (en) * | 2010-06-21 | 2011-12-21 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| US8852593B2 (en) * | 2009-12-18 | 2014-10-07 | Sanofi | Antagonist antibodies and their fab fragments against GPVI and uses thereof |
| EP2402371A1 (en) * | 2010-07-01 | 2012-01-04 | Sanofi | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| EP2336188A1 (en) * | 2009-12-18 | 2011-06-22 | Sanofi-Aventis | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
| WO2012032766A1 (ja) | 2010-09-07 | 2012-03-15 | 持田製薬株式会社 | 血中可溶型ｇｐｖｉを用いたアルツハイマー病の診断方法 |
| CN103396492A (zh) * | 2013-08-06 | 2013-11-20 | 安徽新标志科技有限公司 | 抗人血小板胶原蛋白受体的人源性单克隆抗体片段及其应用 |
| US10395760B2 (en) * | 2015-04-13 | 2019-08-27 | Invitae Corporation | Methods, systems and processes of identifying genetic variation in highly similar genes |
| ES2923677T3 (es) | 2015-08-05 | 2022-09-29 | Acticor Biotech | Novedosos anticuerpos anti-GPVI humanos y usos de los mismos |
| US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
| WO2018126009A1 (en) | 2016-12-29 | 2018-07-05 | University Of Miami | Method for modulating inflammasome activity and inflammation in the lung |
| TW202339799A (zh) | 2017-02-03 | 2023-10-16 | 法商艾提寇生物技術公司 | 使用抗人類ｇｐｖｉ抗體抑制血小板凝集 |
| CN112118869B (zh) * | 2018-05-16 | 2024-10-25 | 莫佛塞斯公司 | 靶向糖蛋白vi的抗体 |
| CN114729036B (zh) * | 2019-09-16 | 2024-07-02 | 奥普西迪奥有限责任公司 | 抗干细胞因子抗体及其使用方法 |
| WO2022082045A1 (en) * | 2020-10-15 | 2022-04-21 | Cornell University | Therapeutic cemip antibodies |
| WO2022257106A1 (zh) * | 2021-06-11 | 2022-12-15 | 江苏丰华生物制药有限公司 | 一种人源化抗人GPVI单克隆抗体Fab片段及其应用 |
| EP4431526A1 (en) | 2023-03-16 | 2024-09-18 | Emfret Analytics GmbH & Co. KG | Anti-gpvi antibodies and functional fragments thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CZ302693B6 (cs) | 1999-05-07 | 2011-09-07 | Aventis Pharma Deutschland Gmbh | Rekombinantní lidský glykoprotein VI, DNA, která ho kóduje a farmaceutický prostredek, který ho obsahuje |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US6245527B1 (en) | 1999-06-30 | 2001-06-12 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof |
| US20040001826A1 (en) | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| AU7097400A (en) | 1999-09-01 | 2001-03-26 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
| EP1224942A1 (en) * | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| EP1430904A4 (en) * | 2001-08-29 | 2005-09-14 | Greenpeptide Co Ltd | desensitizing |
| GB0130543D0 (en) | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| EP1538165A1 (en) | 2003-12-03 | 2005-06-08 | Procorde GmbH | Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4 |
| US20070071744A1 (en) | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
| EP1369128A1 (en) * | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
-
2005
- 2005-04-26 KR KR1020067022571A patent/KR101194446B1/ko not_active IP Right Cessation
- 2005-04-26 EP EP05778408A patent/EP1745076B1/en not_active Not-in-force
- 2005-04-26 ES ES05778408T patent/ES2389047T3/es active Active
- 2005-04-26 CN CN2005800186955A patent/CN1964990B/zh not_active Expired - Fee Related
- 2005-04-26 WO PCT/US2005/014109 patent/WO2005111083A2/en active Application Filing
- 2005-04-26 CA CA002565063A patent/CA2565063A1/en not_active Abandoned
- 2005-04-26 RU RU2006140407/10A patent/RU2407752C2/ru not_active IP Right Cessation
- 2005-04-26 US US11/578,562 patent/US7611707B2/en not_active Expired - Fee Related
- 2005-04-26 JP JP2007510859A patent/JP2008507476A/ja active Pending
- 2005-04-26 AU AU2005243193A patent/AU2005243193B2/en not_active Ceased
- 2005-04-28 TW TW094113726A patent/TW200606177A/zh unknown
- 2005-04-29 AR ARP050101720A patent/AR048638A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101194446B1 (ko) | 2012-10-24 |
| CN1964990B (zh) | 2012-12-12 |
| CA2565063A1 (en) | 2005-11-24 |
| US20070202108A1 (en) | 2007-08-30 |
| EP1745076B1 (en) | 2012-06-13 |
| ES2389047T3 (es) | 2012-10-22 |
| RU2006140407A (ru) | 2008-05-27 |
| AU2005243193A1 (en) | 2005-11-24 |
| EP1745076A2 (en) | 2007-01-24 |
| WO2005111083A3 (en) | 2006-02-09 |
| TW200606177A (en) | 2006-02-16 |
| WO2005111083A2 (en) | 2005-11-24 |
| KR20070010038A (ko) | 2007-01-19 |
| AU2005243193B2 (en) | 2011-01-27 |
| US7611707B2 (en) | 2009-11-03 |
| CN1964990A (zh) | 2007-05-16 |
| RU2407752C2 (ru) | 2010-12-27 |
| JP2008507476A (ja) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048638A1 (es) | Anticuerpos anti-glicoproteina vi y metodos de los mismos | |
| ES2564252T3 (es) | Anticuerpos anti-péptido beta-amiloide N3pGlu y usos de los mismos | |
| PE20061323A1 (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR047611A1 (es) | Formulaciones liquidas de anticuerpos anti-egfr altamente concentradas | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| CO6270369A2 (es) | Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas | |
| PE20091196A1 (es) | Anticuerpos contra el vegf completamente humano, composiciones y metodos | |
| PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
| PE20080891A1 (es) | Anticuerpos anti-notch3 y composiciones que los comprenden | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| ECSP066681A (es) | Formas sólidas de anticuerpos anti-egfr | |
| PE20071055A1 (es) | Anticuerpos anti mn | |
| RS54046B1 (en) | ANTI-MIOSTATIN ANTITELA | |
| GT200600065A (es) | Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20090145A1 (es) | Moleculas de enlace de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) | |
| RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
| PE20120832A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
| UY28641A1 (es) | Anticuerpos | |
| CR11030A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |